Frequency of HLX1-P365T and HLX1-C/T (3′ UTR) polymorphisms in AML and control populations and the relative risk for AML associated with these genotypes
Genotype . | Controls, no. (%) . | AML, no. (%) . | OR (95% CI) . | P . | t-AML, no. (%) . | OR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| HLX1-P365T | |||||||
| CC | 75 (44) | 65 (42) | 1.0‡ | — | 14 (34) | 1.0‡ | — |
| CT | 76 (45) | 76 (49) | 1.15 (0.72-1.83) | .57 | 22 (54) | 1.73 (0.81-3.69) | .16 |
| TT | 19 (11) | 15 (10) | 0.84 (0.39-1.82) | .66 | 5 (12) | 1.02 (0.30-3.51) | .97 |
| CT + TT* | 95 (56) | 91 (58) | 1.08 (0.69-1.69) | .73 | 27 (66) | 1.56 (0.75-3.23) | .23 |
| HLX1-C/T (3′ UTR) | |||||||
| CC | 148 (78) | 126 (76) | 1.0‡ | 22 (52) | 1.0‡ | ||
| CT | 37 (20) | 35 (21) | 1.04 (0.61-1.77) | .90 | 19 (45) | 3.58 (1.73-7.42) | < .001 |
| TT | 4 (2) | 5 (3) | 1.45 (0.38-5.57) | .59 | 1 (2) | 1.48 (0.15-14.25) | .73 |
| CT + TT | 41 (22) | 40 (24) | 1.08 (0.65-1.79) | .78 | 20 (48) | 3.36 (1.65-6.84) | < .001 |
Genotype . | Controls, no. (%) . | AML, no. (%) . | OR (95% CI) . | P . | t-AML, no. (%) . | OR (95% CI) . | P . |
|---|---|---|---|---|---|---|---|
| HLX1-P365T | |||||||
| CC | 75 (44) | 65 (42) | 1.0‡ | — | 14 (34) | 1.0‡ | — |
| CT | 76 (45) | 76 (49) | 1.15 (0.72-1.83) | .57 | 22 (54) | 1.73 (0.81-3.69) | .16 |
| TT | 19 (11) | 15 (10) | 0.84 (0.39-1.82) | .66 | 5 (12) | 1.02 (0.30-3.51) | .97 |
| CT + TT* | 95 (56) | 91 (58) | 1.08 (0.69-1.69) | .73 | 27 (66) | 1.56 (0.75-3.23) | .23 |
| HLX1-C/T (3′ UTR) | |||||||
| CC | 148 (78) | 126 (76) | 1.0‡ | 22 (52) | 1.0‡ | ||
| CT | 37 (20) | 35 (21) | 1.04 (0.61-1.77) | .90 | 19 (45) | 3.58 (1.73-7.42) | < .001 |
| TT | 4 (2) | 5 (3) | 1.45 (0.38-5.57) | .59 | 1 (2) | 1.48 (0.15-14.25) | .73 |
| CT + TT | 41 (22) | 40 (24) | 1.08 (0.65-1.79) | .78 | 20 (48) | 3.36 (1.65-6.84) | < .001 |
The AML patient groups have been compared with the control group and adjusted for age. For HLX1-P365T controls, n = 170; for HLX1-P365T AML, n = 156; and for HLX1-P365T, n = 41. For HLX1-C/T controls, n = 189; for HLX1-C/T AML, n = 166; and for HLX1-C/T t-AML, n = 42.
†Using the χ2 test, for controls versus AML, P = .80; for t-AML, P = .002.
Using the χ2 test, for controls versus AML, P = .75; for t-AML, P = .50.
Used as a reference group.